News Column

Studies from Nanjing Medical University Describe New Findings in Therapeutics and Clinical Risk Management (Safety and efficacy of acarbose in the...

August 8, 2014



Studies from Nanjing Medical University Describe New Findings in Therapeutics and Clinical Risk Management (Safety and efficacy of acarbose in the treatment of diabetes in Chinese patients)

By a News Reporter-Staff News Editor at Health & Medicine Week -- Current study results on Health and Medicine have been published. According to news reporting originating in Jiangsu, People's Republic of China, by NewsRx journalists, research stated, "Acarbose is an alpha-glucosidase inhibitor that is commonly used to control postprandial blood glucose. It functions as a competitive and reversible inhibitor of small intestinal brush border glucosidase, blocks the degradation of starch and sucrose, and delays the absorption of glucose and fructose in the alimentary tract."

The news reporters obtained a quote from the research from Nanjing Medical University, "The starch content of a diet might alter the hypoglycemic effects of acarbose because of its mechanism of action. Chinese individuals consume a typical Eastern diet, which is characterized by a high intake of whole grains, legumes, vegetables, fruits, and fish. These dietary habits allow acarbose to be used extensively in the People's Republic of China. Several Chinese-based studies have demonstrated that the use of acarbose as a monotherapy had similar effects on other anti-diabetes agents in decreasing glycosylated hemoglobin (HbA(1c)) and blood glucose levels, and acarbose in combination with other anti-diabetic drugs could further reduce blood glucose and decrease the mean amplitude of glycemic excursions. Importantly, acarbose is safe and well tolerated, with a low incidence of adverse effects."

According to the news reporters, the research concluded: "This article provides a comprehensive review of the safety and efficacy of acarbose for the treatment of diabetes in Chinese patients."

For more information on this research see: Safety and efficacy of acarbose in the treatment of diabetes in Chinese patients. Therapeutics and Clinical Risk Management, 2014;10():505-511. Therapeutics and Clinical Risk Management can be contacted at: Dove Medical Press Ltd, PO Box 300-008, Albany, Auckland 0752, New Zealand (see also Health and Medicine).

Our news correspondents report that additional information may be obtained by contacting K. He, Nanjing Medical University, Nanjing Hosp 1, Dept. of Endocrinol, Nanjing 210006, Jiangsu, People's Republic of China. Additional authors for this research include J.C. Shi and X.M. Mao.

Keywords for this news article include: Asia, Jiangsu, Glucosidases, Health and Medicine, Enzymes and Coenzymes, People's Republic of China

Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2014, NewsRx LLC


For more stories on investments and markets, please see HispanicBusiness' Finance Channel



Source: Health & Medicine Week


Story Tools






HispanicBusiness.com Facebook Linkedin Twitter RSS Feed Email Alerts & Newsletters